(Q33401747)

English

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean-Charles Soria

9

object named as

Jean Charles Soria

0 references

object named as

Vicente Alfaro

12

0 references

author name string

Christophe Massard

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jane Margetts

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nadia Amellal

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yvette Drew

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ratislav Bahleda

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter Stephens

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean Pierre Armand

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hilary Calvert

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean Charles Soria

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cinthya Coronado

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carmen Kahatt

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mariano Siguero

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carlos Fernández-Teruel

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ruth Plummer

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

12 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

623-630

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-012-9843-5

0 references

Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp..

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

A review of causes and systemic approach to cardiac troponin elevation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9843-5

21 January 2018

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22688291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9843-5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401747&oldid=1536390081"